Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 5;14(1):52.
doi: 10.1007/s13679-025-00644-w.

Unraveling Obesity and Multiple Myeloma: Insights from Epidemiology and Molecular Mechanisms

Affiliations
Review

Unraveling Obesity and Multiple Myeloma: Insights from Epidemiology and Molecular Mechanisms

Linda Manna et al. Curr Obes Rep. .

Abstract

Purpose of review: The global incidence of obesity has risen dramatically in recent decades, with consequent detrimental health effects. Extensive studies have demonstrated that obesity significantly affects the risk, prognosis, and progression of various cancers, including multiple myeloma (MM). As an established modifiable risk factor for both MM and its precursor stages -monoclonal gammopathy of unknown significance (MGUS) and smoldering MM (SMM)- the association between obesity and disease onset has become a compelling area of research. This review presents a comprehensive overview of the current epidemiological evidence linking obesity to MM, emphasizing its role in disease pathogenesis and patient outcomes. It also offers insights into the molecular mechanisms underlying this deleterious association, and discusses therapeutic strategies targeting obesity-driven contributions to MM.

Recent findings: Emerging epidemiological evidence suggests that obesity not only influences MM development but also alters its biological behavior, impacting myelomagenesis, and clinical outcomes. Biologically, multiple pathways exist through which adipose tissue may drive MM onset and progression. Obesity fosters a state of chronic inflammation, where dysfunctional adipocytes and fat-infiltrating immune cells release proinflammatory cytokines, growth factors, adipokines, and fatty acids, contributing to the proliferation and expansion of MM. Additionally, communications between MM cells and adipocytes within the bone marrow are crucial in MM biology. Collectively, the discoveries described in this review underscore the necessity for broader preclinical and clinical investigations to better characterize the complex interplay between obesity and MM, and to determine whether lifestyle interventions can impact MM incidence and clinical outcomes, particularly in high-risk populations.

Keywords: Adipokines; Body mass index; Bone marrow microenvironment; Monoclonal gammopathy of unknown significance; Multiple myeloma; Obesity; Smoldering multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics Approval: Not applicable. Consent to Participate: Not applicable. Consent for Publication: Not applicable. Conflict of interest: The authors have no conficts of interest to declare. Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by any of the authors.

Figures

Fig. 1
Fig. 1
Mechanisms linking obesity with MM. Obesity is correlated with crucial local and systemic variations, including different releases of cytokines, adipokines (mainly leptin), growth factors and inflammatory molecules. The intricate interplay across all these alterations might support MM development, progression and drug resistance. BMAds: bone marrow adipocytes; DHEA: dehydroepiandrosterone; IGF: insulin-like growth factor; iNKTs: invariant natural killer T cells; IFN-γ: interferon gamma; JAK2: Janus kinase 2; LEPR: leptin receptor; MM: multiple myeloma; STAT3: signal transducer and activator of transcription

Similar articles

Cited by

References

    1. Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, et al. NCCN guidelines® insights: multiple myeloma, version 3.2022. J Natl Compr Canc Netw. 2022;20:8–19. - PubMed
    1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63. - PubMed
    1. Brigle K, Rogers B. Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs. 2017;33:225–36. - PubMed
    1. Rajkumar SV, Landgren O, Mateos M-V. Smoldering multiple myeloma. Blood. 2015;125:3069–75. - PMC - PubMed
    1. Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802–24. - PMC - PubMed